Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Collaboration Combines bluebird bio's Gene Editing and Lentiviral Gene Delivery Technologies and Kite's TCR Capabilities and Exclusive Rights to a TCR Directed Against the HPV-16 E6...
-
SANTA MONICA, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), today announced that the Company will host a live webcast in conjunction with its Investor Day on Tuesday,...
-
SANTA MONICA, Calif., June 2, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), today announced clinical biomarker data from patients with relapsed/refractory B cell malignancies treated with...
-
SANTA MONICA, Calif., May 29, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), today announced the Company will report on preliminary biomarker data from patients with relapsed/refractory B...
-
SANTA MONICA, Calif., May 26, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), today announced that Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer, will present...
-
SANTA MONICA, Calif., May 21, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), today announced that the first patient in its Phase 1/2 clinical trial of KTE-C19 in patients with refractory...
-
SANTA MONICA, Calif., May 15, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
-
SANTA MONICA, Calif., May 12, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), today announced that it will release first quarter 2015 financial results on Friday, May 15, 2015. About Kite...
-
SANTA MONICA, Calif., May 4, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), today announced that David D. Chang, M.D., Ph.D., Executive Vice President, Research and Development, and Chief...
-
SANTA MONICA, Calif., April 21, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...